Doximity raised its full-year revenue guidance to US$671–681 million after reporting stronger-than-expected first-quarter fiscal 2027 results, driven by accelerating adoption of its clinical AI tools among physicians.
The stock has rebounded sharply, though compressed margins and declining net income year-on-year temper the optimism, leaving investors divided on valuation and execution risk.
What happened
Doximity reported fiscal Q1 2027 revenue of US$156.62 million, up from US$145.91 million a year earlier, and raised full-year guidance to US$671–681 million (from an earlier target), citing rapid uptake and monetization of its clinical AI tools.
Why it matters
Doximity is betting its growth on converting physician engagement into durable software and marketing revenue, now anchored by AI-powered products. The revenue beat and guidance raise suggest the AI monetization strategy is working, though net income and margins both declined year-on-year, keeping profitability questions in focus.
What to watch
Near-term catalysts hinge on how quickly AI tools translate into contracted revenue and whether large health systems expand adoption. The Simply Wall St Community's fair value estimates span roughly US$18 to just under US$36.72, reflecting divergent views on execution risk and the AI opportunity's credibility.
Ask the AI about this article →
Doximity's fiscal Q1 2027 results mark a turning point in how the healthcare software company is selling itself to investors. For years, Doximity's pitch has centered on converting deep physician engagement into high-margin software and marketing revenue; the latest earnings cycle adds a credible clinical AI angle to that narrative. The revenue beat—coming in ahead of earlier guidance—and the substantial lift to both second-quarter and full-year targets reflect management confidence that AI tools are not just attracting physicians but translating into monetized contracts.
However, the narrowing of margins and the decline in net income year-on-year inject caution into the bull case. The stock's sharp rebound over the past period has already priced in some optimism around the AI push, and the Simply Wall St Community's fair value estimates—ranging from roughly US$18 to just under US$36.72—demonstrate that investors are far from consensus on how much execution risk to accept. Near-term success will depend on whether large health systems move from pilot to scaled adoption of these AI tools and whether that adoption locks in durable, contracted revenue rather than one-time sales.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
AI system scaling has pushed interconnect requirements inside data centers from chips and boards up to racks…
Chinese large-model developer Z.ai says it can now support large-scale inference using roughly 100,000 domesti…
Analyst Ming-Chi Kuo says Nvidia has revived the Rubin CPX AI accelerator with a substantially redesigned arch…
Palantir Technologies stock has posted multi-year gains, including an 11x return over 3 years
Apple has escalated its legal battle against OpenAI, claiming in a new court filing that OpenAI is actively de…
Samsung Electronics has locked up as much as 70% of its memory production capacity under long-term supply agre…
